================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------------------------
FORM 8-K
-----------------------------------------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
September 22, 1997 0-16132
- --------------------------------- ---------------------------------------
Date of Report Commission File Number
(Date of earliest event reported)
CELGENE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 22-2711928
- --------------------------------- ---------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)
7 Powder Horn Drive
Warren, New Jersey 07059
-----------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(908) 271-1001
-----------------------------------------------------
(Registrant's telephone number, including area code)
================================================================================
Item 5. Other Events.
On September 22, 1997, Celgene Corporation (the "Company") issued a
press release announcing that it has received an "approvable letter" from the
U.S. Food and Drug Administration for thalidomide in the treatment of the
cutaneous manifestations of erythema nodosum leprosum, a severe and debilitating
condition associated with leprosy. The press release is filed as an exhibit
hereto and is hereby incorporated by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) not applicable
(b) not applicable
(c) Exhibits
--------
99 Press Release, dated September 22, 1997.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: September 23, 1997 CELGENE CORPORATION
By: /s/ John W. Jackson
-------------------
Name: John W. Jackson
Title: Chairman of the Board and
Chief Executive Officer
3